Neuropharmacologic aspects of the ocular motor system and the treatment of abnormal eye movements.
Neuropharmacology is aiding our understanding of the control of eye movements in at least three ways. First, neurotransmitters have been identified in the pathways that coordinate gaze. Second, the technique of pharmacologic inactivation has provided a powerful method to determine the contributions of populations of neurons to specific behaviors, such as steady gaze holding. Finally, the results of basic neuropharmacologic studies have been used to identify candidate drugs for therapeutic trials of abnormal eye movements.
Leigh
R J
RJ
Department of Neurology, Veterans Affairs Medical Center, Cleveland, Ohio, USA. rjl4@po.cwru.edu
Ramat
S
S
D000010:Abducens Nerve / Q000473:pathology; D000085:Acetates / Q000494:pharmacology / Q000627:therapeutic use*; D000588:Amines; D001418:Baclofen / Q000494:pharmacology / Q000627:therapeutic use*; D003389:Cranial Nerve Diseases / Q000150:complications / Q000473:pathology; D003509:Cyclohexanecarboxylic Acids; D005133:Eye Movements / Q000187:drug effects*; D005403:Fixation, Ocular / Q000187:drug effects / Q000502:physiology; D018755:GABA Agonists / Q000494:pharmacology / Q000627:therapeutic use*; D000077206:Gabapentin; D006801:Humans; D007002:Hypoglossal Nerve / Q000473:pathology; D015835:Ocular Motility Disorders / Q000188:drug therapy* / Q000209:etiology; D014725:Vestibular Nerve / Q000473:pathology; D014795:Visual Pathways / Q000187:drug effects; D005680:gamma-Aminobutyric Acid
D000085:Acetates; D000588:Amines; D003509:Cyclohexanecarboxylic Acids; D018755:GABA Agonists; D005680:gamma-Aminobutyric Acid; D000077206:Gabapentin; D001418:Baclofen